Abstract
BackgroundPrevious studies indicated the calcium-binding protein S100A12 to be involved in the pathophysiology of pulmonary inflammatory diseases. However, the role of S100A12 has remained elusive in patients with community-acquired pneumonia (CAP). Therefore, the purpose of this prospective cohort study was to evaluate the association between serum S100A12 with severity and prognosis in CAP patients.MethodsTwo groups with either 239 CAP patients or 239 healthy controls were enrolled in our study. Fasting blood and clinical characteristics were collected. On admission, serum S100A12 was measured using enzyme-linked immunosorbent assay (ELISA).ResultsSerum S100A12 was increased in CAP patients compared to control subjects. Furthermore, serum S100A12 was elevated according to the severity of CAP. Correlative analysis suggested that the level of serum S100A12 was associated with blood routine indices, renal function markers, inflammatory cytokines and other clinical parameters among CAP patients. Additionally, linear and logistical regression analyses indicated that serum S100A12 was positively associated with CAP severity scores in CAP patients. In addition, the association of high serum S100A12 and prognosis was accessed using a follow-up research. Elevated serum S100A12 on admission increased the risk of death and hospital stay in CAP patients during hospitalization.ConclusionsElevated serum S100A12 on admission is positively associated with the severity and adverse prognosis in CAP patients, suggesting that S100A12 may involve in the pathophysiological process of CAP. The titre of serum S100A12 may be used as a biomarker for diagnosis and prognosis among CAP patients.
Highlights
Community-acquired pneumonia (CAP) which is predominately caused by Steptococcus pneumoniae is one of the most widespread and fatal infectious pathologies
This study found that: [1] serum S100A12 was elevated in CAP patients; [2] serum S100A12 was gradually elevated in line with the severity of CAP; [3] serum S100A12 was positively correlated with CAP severity scores in CAP patients; and [4] serum S100A12 detectable on admission was positively correlated with death and length of hospital stay in CAP patients
This study mainly explored the associations between serum S100A12 with the severity and prognosis among CAP patients using a prospective cohort study
Summary
Community-acquired pneumonia (CAP) which is predominately caused by Steptococcus pneumoniae is one of the most widespread and fatal infectious pathologies. It accounts for approximately 3 million deaths per year worldwide [1]. The annual incidence of CAP diagnosed varies between different communities and ranges from five to 11 cases per 1,000 persons. Timely and accurate evaluation of the disease severity is crucial to stratify patients and to reduce the mortality among the most vulnerable CAP patients. The role of S100A12 has remained elusive in patients with community-acquired pneumonia (CAP). The purpose of this prospective cohort study was to evaluate the association between serum S100A12 with severity and prognosis in CAP patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
